A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia [EXTENSION OF PROFILE 700206660].
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2016
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 02 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 15 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.